RUN heads into the final week of August with a punishing combination: nearly 28% of the free float sold short, a stock down 7.5% over the past month, and a Street that keeps trimming targets even while holding its Buy ratings.
The short position is the defining feature of this setup. At 28% of the free float — with FINRA's fortnightly official count corroborating at 65 million shares — the bearish conviction against Sunrun is substantial and has been creeping higher this week, up roughly 1% over five sessions after falling through most of the month. What makes the short side less explosive than the headline number suggests is the borrow market itself. Availability runs at 328%, meaning lenders hold more than three shares available for every one already borrowed — a loose pool that has tightened only modestly from 400% a month ago. The cost to borrow has collapsed to just 0.27%, down more than 34% on the week and near the lowest levels in the 30-day window. Bears can add exposure cheaply and easily. There is no squeeze pressure here. Options traders are similarly unbothered by downside risk: the put/call ratio of 0.29 sits below its 20-day average of 0.30 and near the 52-week low of 0.25, meaning call buyers still outnumber put buyers. The lopsided call interest looks more like tactical positioning on bounces than genuine bullish conviction, and it has been drifting in this direction for over a month.
The Street tells a story of managed disappointment. After Q2 results on August 5 — when the stock fell nearly 15% in a single session — analysts held their ratings but slashed targets across the board. Goldman Sachs lowered its target to $15 from $18 while keeping Buy. Wells Fargo cut from $22 to $17, also maintaining Overweight. Citi and TD Cowen each moved to $16. RBC trimmed to $14. The consensus message: the thesis is intact but the execution risk is real, and the targets need to come down to reflect it. GLJ Research remains the lone loud bear on the name, reiterating its $4.63 Sell target as recently as August 17 — a figure that, against a $9.19 stock price, implies the bear case still sees meaningful further downside. The factor scores add nuance: EPS momentum over the past 30 and 90 days ranks in the 92nd and 76th percentiles respectively, and EPS surprise ranks at the 90th. The fundamental delivery, at least on an earnings-beat basis, is strong. But the short score of 65.7 — in roughly the 5th percentile for short-score rank — signals that ORTEX's composite short-positioning signal remains firmly bearish.
Institutional flows offer a mildly contrarian data point. Goldman Sachs added 5 million shares in the quarter ending June, lifting its stake to 6.6% of shares outstanding. D.E. Shaw added nearly 3 million shares. Citadel built a position of 4.9 million shares from essentially nothing — a 4.5 million share increase. These are Q2 additions made ahead of the August earnings collapse, so they reflect positioning before the stock lost another 15% in a day, but the names buying are not distressed-dip tourists.
The earnings history underlines why caution is warranted into the next print. The August 5 report produced a 15% one-day drop and a further loss of 11% over the following five days — the sharpest negative reaction in recent history. The prior print in late May did the opposite, gaining 10% on the day before fading 2.5% over the week. The pattern is binary and volatile. The next event is flagged for November 4, which gives the stock roughly ten weeks to either rebuild credibility or deepen the bear case.
The key tension to watch is whether short sellers — who have lowered their position from 66.7 million shares in late July to 64.9 million now — continue to cover or resume building into the next catalyst, and whether the gap between the analyst consensus target (averaging around $15, with the stock at $9.19) starts to attract fresh institutional buyers willing to step in front of the existing short base.
See the live data behind this article on ORTEX.
Open RUN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
